Abstract
The aim of this study was to establish whether combined modality treatment (ABVD plus radiotherapy) can reduce the risk of relapse in Hodgkin's disease patients with mediastinal involvement, as compared to radiotherapy alone. The results obtained suggest that one course of ABVD before irradiation can reduce the incidence of relapse. These findings, however, should be considered preliminary and need to be confirmed in larger studies.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Dacarbazine / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / mortality
-
Hodgkin Disease / pathology
-
Hodgkin Disease / radiotherapy
-
Humans
-
Male
-
Mechlorethamine / administration & dosage
-
Mediastinal Neoplasms / drug therapy*
-
Mediastinal Neoplasms / pathology
-
Mediastinal Neoplasms / radiotherapy
-
Neoplasm Recurrence, Local / prevention & control
-
Prednisone / administration & dosage
-
Procarbazine / administration & dosage
-
Prognosis
-
Remission Induction
-
Salvage Therapy
-
Survival Analysis
-
Treatment Outcome
-
Vinblastine
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Procarbazine
-
Mechlorethamine
-
Vincristine
-
Vinblastine
-
Dacarbazine
-
Doxorubicin
-
Prednisone
Supplementary concepts
-
ABVD protocol
-
MOPP protocol